基于Toll样受体3(TLR3)激动剂PIKA佐剂的加速狂犬病疫苗方案在健康成人志愿者中增强狂犬病毒特异性抗体和T细胞应答
该I期开放标签随机研究将37名健康成人分为3组:对照疫苗经典方案、PIKA疫苗经典方案和PIKA疫苗加速方案,评估安全性、狂犬病毒中和抗体(RVNA)和T细胞应答。PIKA疫苗耐受性良好,加速方案第7天RVNA滴度≥0.5IU/mL的比例为75%,高于PIKA经典方案的53.9%(p=0.411)和对照经典方案的16.7%(p=0.012)。PIKA疫苗诱导的多特异性狂犬病CD4介导T细胞应答在第7天可检测到并维持至第42天。
要点
- PIKA狂犬病疫苗在健康成人中耐受性良好,所有不良事件均为轻度且自限。
- PIKA加速方案第7天RVNA滴度≥0.5IU/mL的比例为75%,高于PIKA经典方案的53.9%(p=0.411)和对照经典方案的16.7%(p=0.012)。
- PIKA疫苗诱导的多特异性狂犬病CD4介导T细胞应答在第7天可检测到并维持至第42天。
核心结论
- 研究性PIKA狂犬病疫苗在健康成人中耐受性良好,且比市售疫苗更具免疫原性。
研究设计与样本
- I期开放标签随机研究,纳入37名健康成人,随机分为3组:对照疫苗经典方案、PIKA疫苗经典方案和PIKA疫苗加速方案。
主要发现
- 对照疫苗和PIKA狂犬病疫苗均耐受性良好,所有不良事件均为轻度且自限。
- PIKA加速方案第7天RVNA滴度≥0.5IU/mL的比例为75%,PIKA经典方案为53.9%(p=0.411),对照经典方案为16.7%(p=0.012)。
- PIKA狂犬病疫苗诱导的多特异性狂犬病CD4介导T细胞应答在接种后第7天可检测到,并维持至第42天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rabies is a fatal disease where post-exposure prophylaxis (PEP) is crucial in preventing infection. However, deaths even after appropriate PEP, have been reported. The PIKA Rabies vaccine adjuvant is a TLR3 agonist that activates B and T cells leading to a robust immune response. METHODS: We conducted a phase I, open label, randomized study in healthy adults to assess the safety and immunogenicity of the PIKA Rabies vaccine and an accelerated vaccine regimen. Thirty-seven subjects were randomized into 3 groups: control vaccine classic regimen, PIKA vaccine classic regimen and PIKA vaccine accelerated regimen. Subjects were followed up for safety, rabies virus neutralizing antibodies (RVNA) and T cell responses. RESULTS: Both the control and PIKA Rabies vaccine were well tolerated. All adverse events (AEs) were mild and self-limiting. Seventy-five percent of subjects in the PIKA accelerated regimen achieved a RVNA titer ⩾0.5IU/mL on day 7, compared to 53.9% in the PIKA classic regimen (p=0.411) and 16.7% in control vaccine classic regimen (p=0.012). The PIKA rabies vaccine elicited multi-specific rabies CD4 mediated T cell response already detectable ex vivo at day 7 after vaccination and that was maintained at day 42. CONCLUSION: The investigational PIKA rabies vaccine was well tolerated and more immunogenic than the commercially available vaccine in healthy adults. Clinical trial registry: The study was registered with clinicaltrials.gov NCT02657161.
引用
- Wijaya L, Tham CYL, Chan YFZ, et al. An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers. Vaccine. 2017. PMID: 28118938. doi:10.1016/j.vaccine.2016.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。